Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1907604 Target Snapshot

Glutamate NMDA receptor; GRIN1/GRIN2A · PROTEIN COMPLEX · Homo sapiens

466Compounds
90Assays
8Approved Drugs
377.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q05586. Use UniProt Q05586 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q05586 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Glutamate NMDA receptor; GRIN1/GRIN2A as ChEMBL target CHEMBL1907604, mapped to UniProt Q05586. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Glutamate NMDA receptor; GRIN1/GRIN2A
PROTEIN COMPLEX · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1907604
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q05586
Glutamate receptor ionotropic, NMDA 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Glutamate NMDA receptor; GRIN1/GRIN2A is the right protein anchor across sources, using UniProt Q05586 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelGlutamate receptor ionotropic, NMDA 1
UniProt AccessionQ05586
Component TypeProtein
Sequence Length938 aa

Glutamate receptor ionotropic, NMDA 1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Glutamate NMDA receptor; GRIN1/GRIN2A, mapped to UniProt Q05586. ChEMBL maps the protein component as Glutamate receptor ionotropic, NMDA 1. Sequence length is 938 aa.

Mapped IDQ05586
Review nameGlutamate NMDA receptor; GRIN1/GRIN2A
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

8
Approved
2
Phase III
5
Phase II
Assay Mix

Activity Type Distribution

IC50203.0
KI7.0
EC50167.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL12513 9.7 IC50 0.2 Preclinical
CHEMBL807 9.02 IC50 0.95 Approved
CHEMBL274422 8.96 IC50 1.1 Preclinical
CHEMBL2398522 8.38 IC50 4.2 Preclinical
CHEMBL536107 8.38 IC50 4.2 Preclinical
CHEMBL1165411 8.01 IC50 9.7 Clinical
CHEMBL55568 7.96 IC50 11.0 Preclinical
CHEMBL395091 7.94 IC50 11.4 Approved
CHEMBL275528 7.93 IC50 11.8 Clinical
CHEMBL3800556 7.75 EC50 17.7 Preclinical
Distribution

pChEMBL Value Distribution

54
5.0
39
5.5
42
6.0
57
6.5
35
7.0
19
7.5
3
8.0
1
8.5
1
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

ESKETAMINE
CHEMBL395091
Approved 2019
MEMANTINE
CHEMBL807
Approved 2002
PENTAMIDINE
CHEMBL55
Approved 1984
KETAMINE
CHEMBL742
Approved 1970
Assay Landscape

Assay Landscape

90
Total Assays
267
Tested Compounds
2
Assay Types
Binding — 79 assays, 267 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 64 200 5.9
protein complex format 13 66 6.2
assay format 1 0
tissue-based format 1 1 5.0
Functional — 11 assays, 25 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 11 25 6.4

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine